Table 3 Clinical characteristics of plwMND
Variable | N (missing N, %) | Mean (SD), median (IQR) or N (%) |
|---|---|---|
Probable or definite MND | 26 (3, 10%) | Â |
 Amyotrophic Lateral Sclerosis |  | 19 (73%) |
 Progressive Muscular Atrophy |  | 1 (4%) |
 Progressive Bulbar Palsy |  | 1 (4%) |
 No MND variant specified |  | 5 (19%) |
Median months since diagnosis | 27 (2, 7%) | 9.0 (25.0), range 0.7–107 |
Median months since symptom onset | 26 (3, 10%) | 27.5 (38.4), range 3–166 |
No. prescribed riluzole | 28 (1, 3%) | 19 (68%) |
ECASa | 29 (0, 0%) | Â |
 Mean total score (possible range 0–136) |  | 111.9 (12.9), range 82–129 |
 Mean ALS-specific total score (possible range 0–100) |  | 83.4 (11.4), range 55–97 |
MiND-B mean total score (possible range 9–36)b | 23 (6, 21%) | 33.1 (3.8), range 24–36 |
No. with a self-reported comorbid physical health diagnosis | 29 (0, 0%) | Â |
 Yes |  | 18 (62%) |
 No |  | 11 (38%) |
No. with a self-reported comorbid mental health diagnosis | 29 (0, 0%) | Â |
 Depression |  | 5 (17%) |
 Anxiety |  | 0 (0%) |
Suicidal ideation | 29 (0, 0%) | Â |
 Yes |  | 5 (17%) |
 No |  | 24 (83%) |
No. prescribed psychotropic medication | 29 (0, 0%) | 10 (34%)c |
 Amitriptyline |  | 2 (10%) |
 Citalopram |  | 5 (25%) |
 Escitalopram |  | 1 (5%) |
 Fluoxetine |  | 1 (5%) |
 Sertraline |  | 1 (5%) |